Elite in Ewing Sarcoma

Franca Fagioli

Turin, IT 
Clinical Trials:Currently Recruiting for 1 Trial
Elite in Ewing Sarcoma
Turin, IT 
OverviewLocationsClinical Research

Overview

Franca Fagioli practices in Turin, Italy. Ms. Fagioli is rated as an Elite expert by MediFind in the treatment of Ewing Sarcoma. Her top areas of expertise are Osteosarcoma, Adult Soft Tissue Sarcoma, Ewing Sarcoma, Bone Marrow Transplant, and Bone Graft.

Her clinical research consists of co-authoring 311 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 19 articles and participated in 2 clinical trials in the study of Ewing Sarcoma.

Gender
Female

Locations

Turin, Italy
Other Locations
Citta, Italy
Piemonte, Italy
Bologna, Italy
Padova, Italy
Sapienza, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia
Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia
Enrollment Status: Recruiting
Publish Date: January 16, 2024
Intervention Type: Drug, Radiation
Study Drugs: VP16, Thiotepa, Treosulfan, Fludarabine, Busulfan, Anti-Thymocyte Globulin, Cyclophosphamide, Grafalon
Study Phase: Phase 2/Phase 3
ABCB1/P-glycoprotein Expression as Biologic Stratification Factor for Patients With Non Metastatic Osteosarcoma - Prospective Study (ISG/OS-2)
ABCB1/P-glycoprotein Expression as Biologic Stratification Factor for Patients With Non Metastatic Osteosarcoma - Prospective Study (ISG/OS-2)
Enrollment Status: Completed
Publish Date: May 20, 2024
Intervention Type: Other, Drug
Study Drug: Mifamurtide
Study Phase: Phase 2
A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients
A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients
Enrollment Status: Completed
Publish Date: March 03, 2023
Intervention Type: Drug, Other
Study Phase: Phase 3
A Prospective Observational Study for Evaluating Incidence, Severity and Outcomes of Chronic Graft-versus-Host Disease According to 2015 NIH Consensus Criteria
A Prospective Observational Study for Evaluating Incidence, Severity and Outcomes of Chronic Graft-versus-Host Disease According to 2015 NIH Consensus Criteria
Enrollment Status: Completed
Publish Date: November 25, 2022
Study With High Doses of Chemotherapy, Radiotherapy and Consolidation Therapy With Ciclofosfamide and Anticyclooxygenase 2, for the Metastatic Ewing Sarcoma
Study With High Doses of Chemotherapy, Radiotherapy and Consolidation Therapy With Ciclofosfamide and Anticyclooxygenase 2, for the Metastatic Ewing Sarcoma
Enrollment Status: Completed
Publish Date: September 19, 2022
Intervention Type: Drug
Study Drugs: TEMIRI, ADM, IFO, CYC, ETO, BUMEL, VIN
Study Phase: Phase 2
Phase III Study on Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma.
Phase III Study on Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma.
Enrollment Status: Completed
Publish Date: September 19, 2022
Intervention Type: Drug
Study Drugs: Standard Treatment (as per Protocol ISG SSG III), Intensified Chemotherapy
Study Phase: Phase 3
A Multi-centre, Multinational, Prospective Observational Registry to Collect Safety and Outcome Data in Patients Diagnosed With Severe Hepatic Veno-occlusive Disease (VOD) Following Hematopoietic Stem Cell Transplantation (HSCT) and Treated With Defitelio®
A Multi-centre, Multinational, Prospective Observational Registry to Collect Safety and Outcome Data in Patients Diagnosed With Severe Hepatic Veno-occlusive Disease (VOD) Following Hematopoietic Stem Cell Transplantation (HSCT) and Treated With Defitelio®
Enrollment Status: Completed
Publish Date: October 16, 2019
Multicentric, Randomized Phase II Trial for the Treatment of Patients With Relapsed Osteosarcoma
Multicentric, Randomized Phase II Trial for the Treatment of Patients With Relapsed Osteosarcoma
Enrollment Status: Terminated
Publish Date: May 13, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 7 Less Clinical Trials

311 Total Publications

A Genomic Sequencing Approach to Newborn Mass Screening and Its Opportunities.
A Genomic Sequencing Approach to Newborn Mass Screening and Its Opportunities.
Journal: JAMA network open
Published: October 17, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Fagioli's expertise for a condition
ConditionClose
View All 22 Advanced Conditions
View All 71 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile